ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Remus Pharmaceuticals delivered 38% YoY consolidated revenue growth for FY26. Management is shifting focus toward higher-margin B2C segments and niche formulations in Latin America and Southeast Asia.
Remus Pharmaceuticals delivered high double-digit revenue growth in H2FY26, driven by aggressive international B2C expansion in Latin America and new specialized therapy launches.
Remus Pharmaceuticals reported FY26 consolidated revenue of ₹8,536 Mn, representing 37.6% growth. The company maintains an asset-light model focusing on complex specialty formulations in semi-regulated markets.